Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13

Journal of Molecular Medicine

Volumn 86, Issue 5, 2008, Pages 541-552

  Merkel, Olaf ^a   Heyder, Christoph ^a   Asslaber, Daniela ^a   Hamacher, Frank ^a   Tinhofer, Inge ^a   Holler, Claudia ^a   Stöcher, Markus ^a   Prokesch, Andreas ^b   Papak, Christine ^b   Scheideler, Marcel ^b   Trajanoski, Zlatko ^b   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Arsenic; Leukaemia; Lymphocyte; Reactive oxidants

Indexed keywords

ARSENIC TRIOXIDE; CD38 ANTIGEN; FLUDARABINE;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL DEATH; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PREDICTION; RISK ASSESSMENT; TREATMENT DURATION;

APOPTOSIS; ARSENICALS; CASPASES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; OXIDATIVE STRESS; OXIDES; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; VIDARABINE;

EID: 43049137635     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0314-6     Document Type: Article

References (40)

1. Lanham S, Hamblin T, Oscier D, Ibbotson R et al (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101:1087-1093
2. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z et al (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029
3. Tinhofer I, Rubenzer G, Holler C, Hofstaetter E et al (2006) Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108:2950-2956
4. Chen L, Widhopf G, Huynh L, Rassenti L et al (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609-4614
5. Wiestner A, Rosenwald A, Barry TS, Wright G et al (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944-4951
6. Stilgenbauer S, Kröber A, Busch R, Eichhorst B et al (2005) 17p deletion predicts for shorter overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: First analysis of the CLL trial of the GCLLSG. Onkologie 28(suppl 3):X-290:29-30
7. Sturm I, Bosanquet AG, Hermann S, Guner D et al (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477-484
8. Lozanski G, Heerema NA, Flinn IW, Smith L et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281
9. Byrd JC, Gribben JG, Peterson BL, Grever MR et al (2006) Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24:437-443
10. Eichhorst BF, Busch R, Hopfinger G, Pasold R et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891
11. Wierda W, O'Brien S, Wen S, Faderl S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078
12. Hillmen P, Skotnicki A, Robak T, Jaksic B et al (2006) Alemtuzumab (CAMPATH(R), MABCAMPATH(R)) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). ASH Annual Meeting Abstracts 108:301
13. Byrd JC, Lin TS, Dalton JT, Wu D et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404
14. Raffoux E, Rousselot P, Poupon J, Daniel MT et al (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334
15. Soignet SL, Maslak P, Wang ZG, Jhanwar S et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348
16. Shen ZY, Shen J, Cai WJ, Hong C et al (2000) The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 5:155-158
17. Park WH, Seol JG, Kim ES, Hyun JM et al (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60:3065-3071
18. Zhou Y, Hileman EO, Plunkett W, Keating MJ et al (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101:4098-4104
19. Kitamura K, Minami Y, Yamamoto K, Akao Y et al (2000) Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14:1743-1750
20. Scholz C, Richter A, Lehmann M, Schulze-Osthoff K et al (2005) Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 24:7031-7042
21. Scholz C, Wieder T, Starck L, Essmann F et al (2005) Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 24:1904-1913
22. Liu Q, Hilsenbeck S, Gazitt Y (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101:4078-4087
23. Cheson BD, Bennett JM, Grever M, Kay N et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997
24. Crespo M, Bosch F, Villamor N, Bellosillo B et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775
25. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F et al (2007) Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics 8:70
26. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353
27. el Rouby S, Thomas A, Costin D, Rosenberg CR et al (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459
28. Pelicano H, Feng L, Zhou Y, Carew JS et al (2003) Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832-37839
29. Bakan N, Taysi S, Yilmaz O, Bakan E et al (2003) Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clin Chim Acta 338:143-149
30. Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268-277
31. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG et al (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111
32. Huang P, Feng L, Oldham EA, Keating MJ et al (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395
33. Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr. et al (2006) Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 107:222-231
34. Taylor BF, McNeely SC, Miller HL, Lehmann GM et al (2006) p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J Pharmacol Exp Ther 318:142-151
35. Damle RN, Temburni S, Calissano C, Yancopoulos S et al (2007) CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110:3352-3359
36. Messmer BT, Messmer D, Allen SL, Kolitz JE et al (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755-764
37. Carew JS, Zhou Y, Albitar M, Carew JD et al (2003) Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17:1437-1447
38. Fayad L, Keating MJ, Reuben JM, O'Brien S et al (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256-263
39. Ono M, Kohda H, Kawaguchi T, Ohhira M et al (1992) Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem Biophys Res Commun 182:1100-1107
40. Dhar SK, Xu Y, Chen Y, St Clair DK (2006) Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J Biol Chem 281:21698-21709